Palvella Therapeutics, Inc. License and Services Revenue (Deprecated 2018-01-31)
Palvella Therapeutics, Inc. (PVLA) reported License and Services Revenue (Deprecated 2018-01-31) of $26.68 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-18.
Discontinued › Income Statement › Other Income
us-gaap:LicenseAndServicesRevenue · last filed 2019-03-18
- Palvella Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2018-12-31 was $4.14M, a 19.20% decline year-over-year.
- Palvella Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2018-09-30 was $7.87M, a 115.70% increase year-over-year.
- Palvella Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $11.22M, a 644.79% increase year-over-year.
- Palvella Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $3.44M, a 241.67% increase year-over-year.
- Palvella Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for fiscal 2018 was $26.68M, a 136.39% increase from fiscal 2017.
- Palvella Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for fiscal 2017 was $11.29M, a 312.46% increase from fiscal 2016.
- Palvella Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for fiscal 2016 was $2.74M.
- Palvella Therapeutics, Inc. license and services revenue (deprecated 2018-01-31) for fiscal 2014 was $473.04K, a 90.83% decline from fiscal 2013.
| Period end | License and Services Revenue (Deprecated 2018-01-31) 3 month | License and Services Revenue (Deprecated 2018-01-31) 6 month | License and Services Revenue (Deprecated 2018-01-31) 9 month | License and Services Revenue (Deprecated 2018-01-31) 12 month | License and Services Revenue (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $4.14M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $12.01M derived: sum of 2 quarters · filed 2019-03-18 | $23.23M derived: sum of 3 quarters · filed 2019-03-18 | $26.68M 10-K · filed 2019-03-18 | |
| 2018-09-30 | $7.87M 10-Q · filed 2018-11-07 | $19.10M derived: sum of 2 quarters · filed 2018-11-07 | $22.54M 10-Q · filed 2018-11-07 | $27.66M derived: sum of 4 quarters · filed 2019-03-18 | |
| 2018-06-30 | $11.22M 10-Q · filed 2018-08-09 | $14.67M 10-Q · filed 2018-08-09 | $19.79M derived: sum of 3 quarters · filed 2019-03-18 | $23.44M derived: sum of 4 quarters · filed 2019-03-18 | |
| 2018-03-31 | $3.44M 10-Q · filed 2018-05-10 | $8.56M derived: sum of 2 quarters · filed 2019-03-18 | $12.21M derived: sum of 3 quarters · filed 2019-03-18 | $13.72M derived: sum of 4 quarters · filed 2019-03-18 | |
| 2017-12-31 | $5.12M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $8.77M derived: sum of 2 quarters · filed 2019-03-18 | $10.28M derived: sum of 3 quarters · filed 2019-03-18 | $11.29M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $3.65M 10-Q · filed 2018-11-07 | $5.16M derived: sum of 2 quarters · filed 2018-11-07 | $6.17M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $1.51M 10-Q · filed 2018-08-09 | $2.52M 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | $1.01M 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | $2.74M 10-K · filed 2018-03-15 | $2.74M 10-K · filed 2017-03-30 | |||
| 2014-12-31 | $473.04K 10-K · filed 2016-03-23 | ||||
| 2013-12-31 | $5.16M 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |